Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
NBIX Neurocrine Biosciences, Inc. monthly Stock Chart
NBIX [NASD]
Neurocrine Biosciences, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E65.41 EPS (ttm)1.84 Insider Own0.90% Shs Outstand92.60M Perf Week-1.22%
Market Cap11.28B Forward P/E23.64 EPS next Y5.08 Insider Trans-24.85% Shs Float88.71M Perf Month-5.87%
Income176.50M PEG- EPS next Q0.74 Inst Own99.05% Short Float5.64% Perf Quarter18.06%
Sales886.80M P/S12.72 EPS this Y74.70% Inst Trans7.14% Short Ratio5.71 Perf Half Y16.55%
Book/sh7.56 P/B15.89 EPS next Y73.72% ROA14.40% Target Price135.20 Perf Year29.20%
Cash/sh8.22 P/C14.62 EPS next 5Y- ROE29.50% 52W Range72.14 - 136.26 Perf YTD11.79%
Dividend- P/FCF38.83 EPS past 5Y19.90% ROI6.00% 52W High-11.82% Beta1.31
Dividend %- Quick Ratio6.70 Sales past 5Y- Gross Margin99.10% 52W Low66.57% ATR4.63
Employees700 Current Ratio6.90 Sales Q/Q71.30% Oper. Margin26.20% RSI (14)42.45 Volatility4.22% 3.62%
OptionableYes Debt/Eq0.00 EPS Q/Q134.40% Profit Margin19.90% Rel Volume1.81 Prev Close120.16
ShortableYes LT Debt/Eq0.59 EarningsAug 03 AMC Payout0.00% Avg Volume876.34K Price120.16
Recom1.90 SMA20-5.78% SMA50-3.35% SMA20011.18% Volume0 Change0.00%
Aug-04-20Downgrade JP Morgan Overweight → Neutral $136
Jun-29-20Downgrade Goldman Buy → Neutral $135
Jun-09-20Initiated Wedbush Outperform $147
Mar-06-20Initiated Citigroup Buy $124
Feb-27-20Initiated Barclays Equal Weight $105
Feb-24-20Initiated William Blair Outperform
Feb-06-20Initiated Mizuho Neutral
Feb-05-20Reiterated H.C. Wainwright Buy $102 → $125
Dec-13-19Downgrade Credit Suisse Outperform → Neutral $110
Aug-07-19Initiated RBC Capital Mkts Outperform $118
Jul-16-19Initiated Oppenheimer Outperform $100
Jun-05-19Initiated Guggenheim Neutral
May-21-19Initiated Credit Suisse Outperform $95
Apr-22-19Upgrade JP Morgan Neutral → Overweight
Apr-12-19Initiated Evercore ISI Outperform
Feb-06-19Reiterated BofA/Merrill Buy $124 → $117
Jan-23-19Downgrade JP Morgan Overweight → Neutral
Dec-13-18Initiated Goldman Buy $103
Nov-21-18Initiated Canaccord Genuity Buy $111
Sep-10-18Initiated Morgan Stanley Overweight $145
Aug-04-20 09:30AM  
Neurocrine Biosciences Inc (NBIX) Q2 2020 Earnings Call Transcript
Motley Fool
08:38AM  
How Is Neurocrine Biosciences' (NASDAQ:NBIX) CEO Paid Relative To Peers?
Simply Wall St.
06:34AM  
How Neurocrine Biosciences Crushed It in Q2
Motley Fool
Aug-03-20 05:15PM  
Neurocrine Biosciences (NBIX) Surpasses Q2 Earnings and Revenue Estimates
Zacks
04:37PM  
Neurocrine Biosciences Stock Pops After Earnings Double, Shatter Views
Investor's Business Daily
04:01PM  
Neurocrine Biosciences Reports Second Quarter 2020 Financial Results
PR Newswire
Jul-30-20 04:01PM  
Neurocrine Biosciences to Participate at the William Blair Biotech Focus Conference 2020
PR Newswire
Jul-27-20 12:31PM  
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
Zacks
Jul-13-20 07:16PM  
Did Hedge Funds Make The Right Call On Neurocrine Biosciences, Inc. (NBIX)?
Insider Monkey
04:01PM  
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2020 Financial Results
PR Newswire
Jul-01-20 07:00AM  
FOCUS-From Parkinson's to peanut allergy, pandemic puts brakes on new drugs
Reuters
Jun-25-20 12:17PM  
The Zacks Analyst Blog Highlights: LLY, ABBV, NBIX and RDY
Zacks
Jun-17-20 04:04PM  
Neurocrine Adds to Pipeline With $2 Billion Takeda Deal
GuruFocus.com
Jun-16-20 07:00AM  
Neurocrine Biosciences and Takeda Announce Collaboration to Develop and Commercialize Potential Therapies for Psychiatric Disorders
Business Wire
Jun-15-20 04:01PM  
Neurocrine Biosciences to Present at the Bank of America Securities 2020 Napa Biopharma Conference
PR Newswire
Jun-08-20 11:01AM  
/C O R R E C T I O N -- Neurocrine Biosciences, Inc./
PR Newswire
Jun-05-20 11:26AM  
Biotech Stock To Watch: Why This Leader Could Be Poised For Another Run
Investor's Business Daily
Jun-04-20 04:01PM  
Neurocrine Biosciences to Present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast
PR Newswire
Jun-03-20 01:44AM  
Edited Transcript of NBIX earnings conference call or presentation 6-May-20 8:30pm GMT
Thomson Reuters StreetEvents
Jun-01-20 11:46AM  
AbbVie Gets FDA Nod for Oriahnn to Control Menstrual Bleeding
Zacks
May-29-20 04:13PM  
FDA Approves the First Oral Medication for the Management of Heavy Menstrual Bleeding Due to Uterine Fibroids in Pre-menopausal Women
PR Newswire
May-26-20 04:01PM  
Neurocrine Biosciences to Present at the Jefferies Virtual Healthcare Conference
PR Newswire
09:39AM  
Are Investors Undervaluing Neurocrine Biosciences, Inc. (NASDAQ:NBIX) By 33%?
Simply Wall St.
May-23-20 08:00AM  
Teladoc, Neurocrine Bio Lead Five Healthy Stocks To Monitor Closely
Investor's Business Daily
May-18-20 12:16PM  
Neurocrine Biosciences Soars Into Buy Zone
Investor's Business Daily Video +6.79%
May-14-20 07:29PM  
Neurocrine Biosciences to Present at the RBC Capital Markets 2020 Global Healthcare Conference
PR Newswire
06:27AM  
Is Now a Good Time To Buy Neurocrine Biosciences?
Motley Fool
May-13-20 04:01PM  
Neurocrine Biosciences to Present Data from its Movement Disorder Portfolio on the American Academy of Neurology Science Highlights Platform
PR Newswire
02:58PM  
The Top 10 Stocks of the Past Decade
Kiplinger
02:38PM  
IBD 50 Stocks To Watch: Top Biotech Scores Price-Target Hikes As It Nears Buy Point
Investor's Business Daily
May-12-20 04:55PM  
This IBD Stock Of The Day Is Setting Up After A Bullish First-Quarter Report
Investor's Business Daily
May-11-20 04:01PM  
Neurocrine Biosciences Exercises Option to License Idorsia's Novel Treatment for Rare Pediatric Epilepsy
PR Newswire
May-07-20 08:09PM  
Neurocrine Biosciences Q1 Beats on Earnings, Revenue
Motley Fool +5.28%
05:30PM  
Neurocrine Biosciences Inc (NBIX) Q1 2020 Earnings Call Transcript
Motley Fool
04:01PM  
Neurocrine Biosciences Announces New Data Published from the Largest Real-World Screening Study, RE-KINECT, Demonstrating that Movements Consistent with Tardive Dyskinesia Occur Frequently and Can Reduce Quality of Life in Patients with Psychiatric Disorders
PR Newswire
May-06-20 05:35PM  
Neurocrine Biosciences (NBIX) Q1 Earnings and Revenues Top Estimates
Zacks
04:01PM  
Neurocrine Biosciences Reports First Quarter 2020 Financial Results
PR Newswire
May-05-20 04:01PM  
Neurocrine Biosciences to Present at Bank of America Merrill Lynch Health Care Conference 2020
PR Newswire
08:35AM  
Is a Surprise Coming for Neurocrine Biosciences (NBIX) This Earnings Season?
Zacks
Apr-29-20 12:34PM  
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
Zacks
Apr-27-20 11:07AM  
Neurocrine Biosciences Parkinson's Drug Cleared by FDA
TheStreet.com
10:24AM  
Neurocrine's stock is up on FDA approval of Parkinson's drug
MarketWatch
07:39AM  
U.S. FDA approves Neurocrine's Parkinson's therapy
Reuters
07:30AM  
Neurocrine Biosciences Announces FDA Approval of Once-Daily ONGENTYS® (opicapone) as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes
PR Newswire
Apr-24-20 11:41AM  
7 Beautiful Biotech Stocks to Buy Here
InvestorPlace
Apr-20-20 01:31PM  
Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?
Simply Wall St.
Apr-15-20 04:01PM  
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2020 Financial Results
PR Newswire
Apr-03-20 08:30AM  
Neurocrine Biosciences Provides COVID-19 Business Update
PR Newswire
Mar-30-20 06:06PM  
FDA Decisions on 5 Drugs Expected in 2nd Quarter
GuruFocus.com
Mar-27-20 12:45PM  
A Trio of Stocks Growing Capex Fast
GuruFocus.com
Mar-26-20 11:40AM  
COLL or NBIX: Which Is the Better Value Stock Right Now?
Zacks
Mar-18-20 02:29PM  
Top Biotech Stocks for Q2 2020
Investopedia -5.65%
Mar-14-20 10:59AM  
Should Neurocrine Biosciences (NASDAQ:NBIX) Be Disappointed With Their 97% Profit?
Simply Wall St.
Mar-11-20 08:53PM  
Hedge Funds Arent Crazy About Neurocrine Biosciences, Inc. (NBIX) Anymore
Insider Monkey -6.87%
02:45PM  
Stock Upgrades: Neurocrine Biosciences Shows Rising Relative Strength
Investor's Business Daily
Mar-10-20 11:40AM  
COLL or NBIX: Which Is the Better Value Stock Right Now?
Zacks
Mar-05-20 02:38PM  
Neurocrine Biosciences Stock Rating Jumps Amid Expanded Use Plans
Investor's Business Daily
Feb-25-20 04:01PM  
Neurocrine Biosciences to Present at Cowen 40th Annual Health Care Conference
PR Newswire
Feb-19-20 12:08PM  
Neurocrine Biosciences Earns Membership In 95-Plus Composite Rating Club
Investor's Business Daily
Feb-15-20 07:37AM  
Edited Transcript of NBIX earnings conference call or presentation 4-Feb-20 9:30pm GMT
Thomson Reuters StreetEvents
Feb-07-20 09:28AM  
Earnings Miss: Neurocrine Biosciences, Inc. Missed EPS By 52% And Analysts Are Revising Their Forecasts
Simply Wall St.
Feb-05-20 09:35AM  
Can Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Improve Its Returns?
Simply Wall St.
Feb-04-20 05:55PM  
Neurocrine Biosciences (NBIX) Q4 Earnings Lag Estimates
Zacks
04:01PM  
Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2019 Financial Results
PR Newswire
07:51AM  
The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares
Benzinga
Feb-03-20 05:00PM  
Neurocrine Biosciences Announces Appointment of Shalini Sharp to Board of Directors
PR Newswire
08:33AM  
The Zacks Analyst Blog Highlights: Waters, Neurocrine Biosciences, Spirit Airlines, NuStar Energy and The RMR Group
Zacks
Feb-02-20 01:04PM  
The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus
Benzinga
Jan-31-20 09:15AM  
Late Rally Lifts Stocks Despite Coronavirus Concerns
Zacks
07:48AM  
5 Top Stocks Set to Beat Earnings Estimates Next Week
Zacks
07:16AM  
Bet on Earnings Beat With 5 Top-Ranked Stocks
Zacks
Jan-28-20 12:31PM  
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
Zacks
Jan-20-20 04:30PM  
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2019 Financial Results
PR Newswire
10:02AM  
Zacks.com featured highlights include: Zumiez, Neurocrine Biosciences and Covanta
Zacks
Jan-17-20 08:22AM  
Look Beyond Earnings Growth, Tap the Beat With These 3 Stocks
Zacks
Jan-13-20 08:30AM  
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2020 and Provides Corporate Update
GlobeNewswire -8.37%
Jan-12-20 06:30PM  
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2019 Net Product Sales Results and 2020 Program Milestones
PR Newswire
Jan-10-20 11:40AM  
AMRX vs. NBIX: Which Stock Is the Better Value Option?
Zacks
01:00AM  
Neurocrine Biosciences and Idorsia Amend Option Agreement to License Novel Treatment for Rare Pediatric Epilepsy
PR Newswire
Jan-09-20 12:10PM  
Will Neurocrine (NBIX) Beat Estimates Again in Its Next Earnings Report?
Zacks
Jan-06-20 04:01PM  
Neurocrine Biosciences to Present at the 38th Annual J.P. Morgan Healthcare Conference Live Audio Webcast will be on January 13, 2020
PR Newswire
10:31AM  
Is Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) CEO Pay Fair?
Simply Wall St.
Dec-25-19 03:12PM  
How Did Neurocrine Biosciences, Inc. (NBIX) Compare Against Top Hedge Fund Stocks in 2019?
Insider Monkey
Dec-23-19 07:06PM  
3 Breakout Stocks of the Last Decade to Consider for 2020
Zacks
01:01AM  
S&P Rises for Fourth Straight Week
Zacks
Dec-19-19 07:05AM  
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
Zacks
Dec-07-19 08:45AM  
Xenon Pharmaceuticals Provides Updates on Partnered Neurology Pipeline Programs at the 2019 American Epilepsy Society (AES) Annual Meeting
GlobeNewswire
Dec-06-19 11:11AM  
With EPS Growth And More, Neurocrine Biosciences (NASDAQ:NBIX) Is Interesting
Simply Wall St.
Dec-03-19 07:59AM  
The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial
Benzinga
Dec-02-19 07:30AM  
Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy
GlobeNewswire
Nov-27-19 06:52AM  
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
Zacks
Nov-26-19 11:54PM  
Hedge Funds Have Never Been This Bullish On Neurocrine Biosciences, Inc. (NBIX)
Insider Monkey
Nov-12-19 04:01PM  
Neurocrine Biosciences Publishes Long-Term INGREZZA® (valbenazine) Data in the Journal of Clinical Psychopharmacology Demonstrating Once-Daily 40 mg and 80 mg Capsules Reduced Involuntary Movements in Adults with Tardive Dyskinesia
PR Newswire
Nov-10-19 12:50AM  
Edited Transcript of NBIX earnings conference call or presentation 4-Nov-19 9:30pm GMT
Thomson Reuters StreetEvents
Nov-05-19 04:01PM  
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
PR Newswire
Nov-04-19 07:15PM  
Neurocrine Biosciences (NBIX) Beats Q3 Earnings and Revenue Estimates
Zacks
04:01PM  
Neurocrine Biosciences Reports Third Quarter 2019 Financial Results
PR Newswire
01:38PM  
Is Neurocrine Biosciences (NASDAQ:NBIX) A Risky Investment?
Simply Wall St.
Nov-01-19 08:53AM  
Why Earnings Season Could Be Great for Neurocrine Biosciences (NBIX)
Zacks
Oct-28-19 10:32AM  
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
Zacks
Neurocrine Biosciences, Inc., a commercial-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of neurological, endocrine, and psychiatric disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) for the treatment of tardive dyskinesia; and ORILISSA, a gonadotropin-releasing hormone antagonist for use in the treatment of endometriosis. Its product candidates in clinical development include elagolix that has completed Phase III clinical trial for uterine fibroids; opicapone, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBIb-1817, an AADC gene replacement therapy, which is in Phase II clinical trial for the treatment of Parkinson's disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients with SCN8A-DEE, as well as other indications, such as adult focal epilepsy; ACT-709478, an orally active and brain penetrating T-type calcium channel blocker for use in certain forms of generalized epilepsy; and VMAT2 inhibitor for the treatment of various neurology and/or psychiatry disorders. Neurocrine Biosciences, Inc. has collaborations and agreements with AbbVie Inc.; BIAL A Portela & Ca, S.A.; Voyager Therapeutics, Inc.; Xenon Pharmaceuticals Inc.; Mitsubishi Tanabe Pharma Corporation; Idorsia Pharmaceuticals Ltd; and Takeda Pharmaceutical Company Limited. The company was founded in 1992 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lippoldt DarinChief Legal OfficerJul 09Option Exercise35.991,65759,63527,678Jul 10 04:26 PM
Lippoldt DarinChief Legal OfficerJul 09Sale136.021,657225,38626,021Jul 10 04:26 PM
Lippoldt DarinChief Legal OfficerJun 23Option Exercise32.995,000164,95031,021Jun 25 04:15 PM
ROBERTS EIRYChief Medical OfficerJun 23Option Exercise77.815,000389,05014,416Jun 25 04:19 PM
Lippoldt DarinChief Legal OfficerJun 23Sale130.005,000650,00026,021Jun 25 04:15 PM
ROBERTS EIRYChief Medical OfficerJun 23Sale130.005,000650,0009,416Jun 25 04:19 PM
Grigoriadis Dimitri E.Chief Research OfficerJun 11Option Exercise35.905,571199,97677,563Jun 15 05:31 PM
Grigoriadis Dimitri E.Chief Research OfficerMay 19Option Exercise35.9910,000359,900114,741May 20 06:59 PM
Grigoriadis Dimitri E.Chief Research OfficerMay 19Sale126.5542,7495,409,93371,992May 20 06:59 PM
Lippoldt DarinChief Legal OfficerMay 18Option Exercise32.995,000164,95031,021May 20 07:15 PM
Grigoriadis Dimitri E.Chief Research OfficerMay 18Option Exercise35.9910,000359,900114,741May 20 06:59 PM
Lippoldt DarinChief Legal OfficerMay 18Sale120.005,000600,00026,021May 20 07:15 PM
Grigoriadis Dimitri E.Chief Research OfficerMay 18Sale119.9810,0001,199,800104,741May 20 06:59 PM
Bozigian Haig P.Chief Development OfficerMay 12Option Exercise63.1061,5553,884,054167,204May 14 08:09 PM
Bozigian Haig P.Chief Development OfficerMay 12Sale114.9461,5557,075,396148,633May 14 08:09 PM
ABERNETHY MATTChief Financial OfficerMay 07Option Exercise73.6015,0001,104,00020,953May 11 08:17 PM
Grigoriadis Dimitri E.Chief Research OfficerMay 07Sale105.448,682915,454104,741May 11 08:06 PM
ABERNETHY MATTChief Financial OfficerMay 07Sale110.2115,0001,653,1345,953May 11 08:17 PM
SHERWIN STEPHEN ADirectorApr 28Sale99.3917,6871,757,96629,861Apr 30 04:27 PM
ABERNETHY MATTChief Financial OfficerApr 28Sale102.491,741178,4355,953Apr 30 04:25 PM
ABERNETHY MATTChief Financial OfficerApr 24Sale99.521,934192,4677,694Apr 28 08:32 PM
ROBERTS EIRYChief Medical OfficerApr 24Sale99.471,934192,3769,416Apr 28 08:46 PM
Lloyd-Smith MalcolmChief Regulatory OfficerApr 24Sale99.451,934192,32924,941Apr 28 08:44 PM
Lippoldt DarinChief Legal OfficerApr 24Sale99.491,934192,41626,021Apr 28 08:43 PM
Grigoriadis Dimitri E.Chief Research OfficerApr 24Sale99.411,934192,258113,423Apr 28 08:42 PM
GORMAN KEVIN CHARLESChief Executive OfficerApr 24Sale99.452,906289,016434,971Apr 28 08:41 PM
Gano KyleChief Business Development OffApr 24Sale99.471,934192,37793,967Apr 28 08:40 PM
Cooke JulieChief Human Resources OfficerApr 24Sale99.461,934192,3646,631Apr 28 08:38 PM
Bozigian Haig P.Chief Development OfficerApr 24Sale99.461,934192,351148,633Apr 28 08:35 PM
BENEVICH ERICChief Commercial OfficerApr 24Sale99.451,934192,33813,344Apr 28 08:33 PM
BENEVICH ERICChief Commercial OfficerApr 15Sale94.658,632817,01811,603Apr 17 09:48 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 10Option Exercise59.6628,9691,728,14739,127Feb 11 07:21 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 10Sale104.5628,9693,029,08623,200Feb 11 07:21 PM
ROBERTS EIRYChief Medical OfficerFeb 07Sale103.311,623167,6757,452Feb 11 07:23 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 07Sale103.281,015104,82723,200Feb 11 07:21 PM
Lippoldt DarinChief Legal OfficerFeb 07Sale103.321,522157,24724,124Feb 11 07:17 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 07Sale103.311,218125,833111,682Feb 11 07:16 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 07Sale103.353,248335,696432,357Feb 11 07:14 PM
Gano KyleChief Business Development OffFeb 07Sale103.331,623167,71091,975Feb 11 07:13 PM
Cooke JulieChief Human Resources OfficerFeb 07Sale103.2691394,2764,643Feb 11 07:10 PM
Bozigian Haig P.Chief Development OfficerFeb 07Sale103.331,623167,702146,641Feb 11 07:09 PM
BENEVICH ERICChief Commercial OfficerFeb 07Sale103.322,030209,74720,087Feb 11 07:08 PM
ABERNETHY MATTChief Financial OfficerFeb 07Sale103.352,030209,8075,701Feb 11 07:06 PM
BENEVICH ERICChief Commercial OfficerFeb 06Sale101.481,395141,56118,262Feb 07 06:35 PM
Bozigian Haig P.Chief Development OfficerFeb 06Sale101.561,395141,670145,180Feb 07 06:37 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 06Sale101.564,343441,068429,436Feb 07 06:44 PM
Lippoldt DarinChief Legal OfficerFeb 06Sale101.471,198121,55622,755Feb 07 06:46 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 06Sale101.521,490151,25822,287Feb 07 06:47 PM
Gano KyleChief Business Development OffFeb 06Sale101.411,000101,41390,514Feb 07 06:54 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 06Sale101.4480381,456110,587Feb 07 06:50 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 05Sale103.151,618166,894109,320Feb 07 06:50 PM
Gano KyleChief Business Development OffFeb 05Sale103.053,690380,26287,204Feb 07 06:54 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 05Sale103.051,948200,73320,455Feb 07 06:47 PM
Lippoldt DarinChief Legal OfficerFeb 05Sale102.981,750180,20721,133Feb 07 06:46 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 05Sale103.095,449561,726423,351Feb 07 06:44 PM
Cooke JulieChief Human Resources OfficerFeb 05Sale103.1760562,4173,821Feb 07 06:38 PM
Bozigian Haig P.Chief Development OfficerFeb 05Sale103.022,046210,779143,292Feb 07 06:37 PM
BENEVICH ERICChief Commercial OfficerFeb 05Sale103.031,954201,31116,279Feb 07 06:35 PM
ROBERTS EIRYChief Medical OfficerJan 08Sale111.112,632292,4455,991Jan 10 04:10 PM
ABERNETHY MATTChief Financial OfficerDec 02Sale116.331,645191,3603,876Dec 04 06:06 PM
Grigoriadis Dimitri E.Chief Research OfficerNov 18Option Exercise35.995,000179,950113,408Nov 19 05:37 PM
Grigoriadis Dimitri E.Chief Research OfficerNov 18Sale115.985,000579,900108,408Nov 19 05:37 PM
Lippoldt DarinChief Legal OfficerNov 08Option Exercise32.9910,000329,90026,728Nov 13 04:36 PM
LYONS GARY ADirectorNov 08Sale110.005,000550,000225,697Nov 13 04:41 PM
Lippoldt DarinChief Legal OfficerNov 08Sale110.0110,0001,100,05720,103Nov 13 04:36 PM
Grigoriadis Dimitri E.Chief Research OfficerNov 01Option Exercise32.9910,188336,102118,596Nov 05 04:37 PM
LYONS GARY ADirectorNov 01Sale100.225,000501,104230,697Nov 05 04:38 PM
Grigoriadis Dimitri E.Chief Research OfficerNov 01Sale100.3410,1881,022,298108,408Nov 05 04:37 PM
Lloyd-Smith MalcolmChief Regulatory OfficerOct 14Option Exercise15.459,956153,82029,569Oct 16 04:20 PM
Lloyd-Smith MalcolmChief Regulatory OfficerOct 14Sale90.859,956904,48719,613Oct 16 04:20 PM
Cooke JulieChief Human Resources OfficerOct 02Sale88.5698787,4093,276Oct 04 06:15 PM
Lippoldt DarinChief Legal OfficerSep 03Option Exercise32.996,736222,22126,839Sep 05 04:09 PM
Lippoldt DarinChief Legal OfficerSep 03Sale100.006,736673,60020,103Sep 05 04:09 PM
Lippoldt DarinChief Legal OfficerAug 27Option Exercise32.991,60052,78421,561Aug 27 07:52 PM
Lippoldt DarinChief Legal OfficerAug 27Sale100.001,600160,00019,961Aug 27 07:52 PM
Lippoldt DarinChief Legal OfficerAug 23Option Exercise32.991,66454,89521,625Aug 27 07:52 PM
Lippoldt DarinChief Legal OfficerAug 23Sale100.091,664166,55519,961Aug 27 07:52 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 09Option Exercise32.993,03199,993420,628Aug 13 04:44 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 08Option Exercise8.6626,330228,018443,927Aug 08 07:39 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 08Sale95.6426,3302,518,154417,597Aug 08 07:39 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 07Option Exercise8.662,75923,893420,356Aug 08 07:39 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 07Sale95.122,759262,440417,597Aug 08 07:39 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 06Option Exercise8.6650,911440,889468,508Aug 08 07:39 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 06Sale95.1550,9114,844,380417,597Aug 08 07:39 PM
open in yahoo | open in reuters | open in google